Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cytokinetics Incorporated's Business Segments
Cytokinetics Incorporated's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Net Product Revenue
Total Revenue
$ 29
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Net Product Revenue0%
- License and Milestone Revenues41.6%
- Development and Commercial Milestones34.9%
- Collaboration Revenues16.4%
- CN4.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Net Product Revenue | $ 30 | - |
| License and Milestone Revenues | $ 12 | 41.6% |
| Development and Commercial Milestones | $ 10 | 34.9% |
2 more segments available
Sign in to unlock the full Cytokinetics Incorporated dataset.
Revenue by Product & Service Category - FY
- License and Milestone Revenues61.6%
- Net Product Revenue24.7%
- Collaboration Revenues13.6%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Milestone Revenues | $ 12 | 61.6% |
| Net Product Revenue | $ 5 | 24.7% |
| Collaboration Revenues | $ 3 | 13.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Net Product Revenue0%
- License and Milestone Revenues41.6%
- Development and Commercial Milestones34.9%
- Collaboration Revenues16.4%
- CN4.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Net Product Revenue | $ 30 | - |
| License and Milestone Revenues | $ 12 | 41.6% |
| Development and Commercial Milestones | $ 10 | 34.9% |
2 more segments available
Sign in to unlock the full Cytokinetics Incorporated dataset.
Description of Cytokinetics Incorporated
Cytokinetics Incorporated is a biopharmaceutical company that is dedicated to developing small molecule drugs that can be used to treat a variety of diseases. The company was founded in 1997 and is headquartered in South San Francisco, California. Since its inception, Cytokinetics has focused on developing drugs that can enhance the function of the muscles in the body, with an emphasis on skeletal and cardiac muscle.
Cytokinetics has developed a number of investigational drugs that are intended to improve the function of the heart and skeletal muscles. The company has developed a drug called omecamtiv mecarbil that is intended to improve the contractility of cardiac muscle. This drug is currently being tested in several clinical trials for the treatment of heart failure. Cytokinetics has also developed a drug called reldesemtiv that is intended to improve skeletal muscle function in people with amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
In addition to its investigational drugs, Cytokinetics has developed a number of partnerships with other companies and academic institutions. The company has partnered with companies like Amgen and Astellas to advance and develop its investigational drugs. It has also worked with academic institutions like the University of California, San Francisco and the University of Michigan to further explore the science behind its drug development.
Cytokinetics has received numerous grants and awards for its drug development efforts. In 2013, the company received a grant from the National Institute of Neurological Disorders and Stroke to support the development of reldesemtiv for the treatment of ALS. The company has also been recognized by the California Institute for Regenerative Medicine for its work in developing cell therapy approaches for heart disease.
Overall, Cytokinetics has established itself as a leader in the development of drugs that can improve muscle function in a variety of diseases. Its investigational drugs have the potential to improve patient outcomes and benefit the field of medicine as a whole.
Cytokinetics has developed a number of investigational drugs that are intended to improve the function of the heart and skeletal muscles. The company has developed a drug called omecamtiv mecarbil that is intended to improve the contractility of cardiac muscle. This drug is currently being tested in several clinical trials for the treatment of heart failure. Cytokinetics has also developed a drug called reldesemtiv that is intended to improve skeletal muscle function in people with amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
In addition to its investigational drugs, Cytokinetics has developed a number of partnerships with other companies and academic institutions. The company has partnered with companies like Amgen and Astellas to advance and develop its investigational drugs. It has also worked with academic institutions like the University of California, San Francisco and the University of Michigan to further explore the science behind its drug development.
Cytokinetics has received numerous grants and awards for its drug development efforts. In 2013, the company received a grant from the National Institute of Neurological Disorders and Stroke to support the development of reldesemtiv for the treatment of ALS. The company has also been recognized by the California Institute for Regenerative Medicine for its work in developing cell therapy approaches for heart disease.
Overall, Cytokinetics has established itself as a leader in the development of drugs that can improve muscle function in a variety of diseases. Its investigational drugs have the potential to improve patient outcomes and benefit the field of medicine as a whole.
Cytokinetics Incorporated is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative muscle-directed medicines, targeting debilitating diseases with significant unmet medical needs. Their primary focus lies in developing small molecule therapeutics that enhance muscle function across a variety of medical conditions, including heart failure, amyotrophic lateral sclerosis (ALS), hypertrophic cardiomyopathy, and spinal muscular atrophy.
Segments
Cytokinetics operates within a unified business segment that encompasses all aspects of drug discovery, development, and commercialization of their muscle-directed therapies. This segment is characterized by a holistic approach to the development of novel therapeutic agents with the aim of directly targeting muscle function and performance, which is pivotal in managing diseases that compromise muscular and cardiac systems.
Products
The product pipeline at Cytokinetics is rich with advanced small molecule therapeutics, thoughtfully engineered for direct action on muscle tissues. Key products currently in development include:
1. Omecamtiv Mecarbil:
- Indication: Developed in collaboration with Amgen, Omecamtiv Mecarbil is aimed at the treatment of heart failure.
- Mechanism of Action: As a cardiac myosin activator, Omecamtiv Mecarbil selectively enhances myocardial contractility, leading to improved cardiac muscle function.
- Clinical Development: The drug has undergone various phases of clinical trials and has revealed promising safety and efficacy profiles, showcasing potential benefits in heart failure management.
2. Reldesemtiv:
- Indications: Reldesemtiv is being investigated for spinal muscular atrophy, ALS, and additional neuromuscular disorders.
- Mechanism of Action: This therapeutic agent acts as a fast skeletal muscle troponin activator, which boosts muscle contractility and endurance by enhancing the efficiency of muscle fiber contraction during exercise or physical activity.
- Clinical Development: Continued research and clinical evaluations underline its potential in ameliorating symptoms associated with muscle weakness in neuromuscular conditions.
3. CK-274:
- Indication: Targeted for patients suffering from hypertrophic cardiomyopathy, a condition marked by excessive heart muscle thickness.
- Mechanism of Action: CK-274 serves as a cardiac myosin inhibitor, specifically crafted to mitigate the pathological contractility associated with this disease. By reducing the overactive contraction of heart muscle cells, CK-274 aims to alleviate the symptoms of hypertrophic cardiomyopathy.
- Clinical Development: The development of CK-274 is substantiated by positive results from clinical trials, which have highlighted its therapeutic potential.
Services
Beyond drug development, Cytokinetics offers a suite of services designed to facilitate and enhance research and development processes in the biopharmaceutical realm. These services include:
1. Preclinical Services:
- Cytokinetics provides robust preclinical support that encompasses a wide range of capabilities such as drug synthesis, pharmacological evaluations, toxicology testing, and formulation development. This foundational stage is crucial for validating drug candidates before they progress into clinical testing.
2. Clinical Trial Management:
- With extensive expertise in managing clinical trials, Cytokinetics offers comprehensive services that include the creation and refinement of trial protocols, efficacious site management, recruitment of study participants, and meticulous data management. Their proficiency in clinical trial operations ensures that studies are conducted efficiently and in compliance with regulatory standards.
3. Scientific Consulting:
- Cytokinetics leverages its in-depth knowledge of muscle biology and pharmacology to provide scientific consulting services to collaborators in the industry. They assist clients in strategizing drug development pathways, optimizing clinical trial designs, and addressing specific challenges encountered in muscle-directed therapeutics development.
In summary, Cytokinetics Incorporated stands at the forefront of developing transformative treatments that directly address muscle dysfunction associated with a range of debilitating diseases. Their portfolio includes promising small molecule drugs tailored to improve muscle function and performance, supported by comprehensive preclinical, clinical, and consulting services that exemplify their commitment to realizing advancements in biomedicine.
Segments
Cytokinetics operates within a unified business segment that encompasses all aspects of drug discovery, development, and commercialization of their muscle-directed therapies. This segment is characterized by a holistic approach to the development of novel therapeutic agents with the aim of directly targeting muscle function and performance, which is pivotal in managing diseases that compromise muscular and cardiac systems.
Products
The product pipeline at Cytokinetics is rich with advanced small molecule therapeutics, thoughtfully engineered for direct action on muscle tissues. Key products currently in development include:
1. Omecamtiv Mecarbil:
- Indication: Developed in collaboration with Amgen, Omecamtiv Mecarbil is aimed at the treatment of heart failure.
- Mechanism of Action: As a cardiac myosin activator, Omecamtiv Mecarbil selectively enhances myocardial contractility, leading to improved cardiac muscle function.
- Clinical Development: The drug has undergone various phases of clinical trials and has revealed promising safety and efficacy profiles, showcasing potential benefits in heart failure management.
2. Reldesemtiv:
- Indications: Reldesemtiv is being investigated for spinal muscular atrophy, ALS, and additional neuromuscular disorders.
- Mechanism of Action: This therapeutic agent acts as a fast skeletal muscle troponin activator, which boosts muscle contractility and endurance by enhancing the efficiency of muscle fiber contraction during exercise or physical activity.
- Clinical Development: Continued research and clinical evaluations underline its potential in ameliorating symptoms associated with muscle weakness in neuromuscular conditions.
3. CK-274:
- Indication: Targeted for patients suffering from hypertrophic cardiomyopathy, a condition marked by excessive heart muscle thickness.
- Mechanism of Action: CK-274 serves as a cardiac myosin inhibitor, specifically crafted to mitigate the pathological contractility associated with this disease. By reducing the overactive contraction of heart muscle cells, CK-274 aims to alleviate the symptoms of hypertrophic cardiomyopathy.
- Clinical Development: The development of CK-274 is substantiated by positive results from clinical trials, which have highlighted its therapeutic potential.
Services
Beyond drug development, Cytokinetics offers a suite of services designed to facilitate and enhance research and development processes in the biopharmaceutical realm. These services include:
1. Preclinical Services:
- Cytokinetics provides robust preclinical support that encompasses a wide range of capabilities such as drug synthesis, pharmacological evaluations, toxicology testing, and formulation development. This foundational stage is crucial for validating drug candidates before they progress into clinical testing.
2. Clinical Trial Management:
- With extensive expertise in managing clinical trials, Cytokinetics offers comprehensive services that include the creation and refinement of trial protocols, efficacious site management, recruitment of study participants, and meticulous data management. Their proficiency in clinical trial operations ensures that studies are conducted efficiently and in compliance with regulatory standards.
3. Scientific Consulting:
- Cytokinetics leverages its in-depth knowledge of muscle biology and pharmacology to provide scientific consulting services to collaborators in the industry. They assist clients in strategizing drug development pathways, optimizing clinical trial designs, and addressing specific challenges encountered in muscle-directed therapeutics development.
In summary, Cytokinetics Incorporated stands at the forefront of developing transformative treatments that directly address muscle dysfunction associated with a range of debilitating diseases. Their portfolio includes promising small molecule drugs tailored to improve muscle function and performance, supported by comprehensive preclinical, clinical, and consulting services that exemplify their commitment to realizing advancements in biomedicine.